Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

African oncologists interaction with pharmaceutical industry

Choosing Wisely Tanzania 2023

9 - 10 Feb 2023

Published: 22 Mar 2023

Views: 96

Rating:

Save

Prof Nazik Hammad - Queen's University, Kingston, Canada

Prof Nazik Hammad delivers her presentation at Choosing Wisely Tanzania 2023 on 'African oncologists interaction with pharmaceutical industry'.

She begins by discussing the influence of pharmaceutical companies on clinics and how this affects decisions of physicians.

Prof Hammad goes on to explain the risks of industry-oncologist interactions and potential ways to mitigate them.

Related Videos

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

The role of the workforce in implementing Choosing Wisely in cancer care

Prof Nazik Hammad - Queen's University, Kingston, Canada

The role of the workforce in implementing Choosing Wisely in cancer care ( Prof Nazik Hammad - Queen's University, Kingston, Canada )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

More from ecancer